V
Veerendra Munugalavadla
Researcher at Genentech
Publications - 19
Citations - 401
Veerendra Munugalavadla is an academic researcher from Genentech. The author has contributed to research in topics: Protein kinase B & Haematopoiesis. The author has an hindex of 11, co-authored 19 publications receiving 348 citations. Previous affiliations of Veerendra Munugalavadla include Indiana University & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL
Raghuveer Singh Mali,Baskar Ramdas,Peilin Ma,Jianjian Shi,Veerendra Munugalavadla,Emily Sims,Lei Wei,Sasidhar Vemula,Sarah C. Nabinger,Charles B. Goodwin,Rebecca J. Chan,Fabiola Traina,Valeria Visconte,Ramon V. Tiu,Timothy A. Lewis,Andrew M. Stern,Qiang Wen,John D. Crispino,H. Scott Boswell,Reuben Kapur +19 more
TL;DR: A pathway involving PI3K/Rho/ROCK/MLC that may contribute to myeloproliferative disease and/or acute myeloid leukemia in humans is described.
Journal ArticleDOI
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT
Raghuveer Singh Mali,Peilin Ma,Li-Fan Zeng,Holly Martin,Baskar Ramdas,Yantao He,Emily Sims,Sarah C. Nabinger,Joydeep Ghosh,Namit Sharma,Veerendra Munugalavadla,Anindya Chatterjee,Shuo Li,George E. Sandusky,Andrew W.B. Craig,Kevin D. Bunting,Gen-Sheng Feng,Rebecca J. Chan,Zhong Yin Zhang,Reuben Kapur +19 more
TL;DR: The results demonstrate that SHP2 phosphatase is a druggable target that cooperates with lipid kinases in inducing MPD and shows that a single tyrosine at position 719 in oncogenic KIT is sufficient to develop MPD.
Journal ArticleDOI
Pak and Rac GTPases promote oncogenic KIT–induced neoplasms
Holly Martin,Raghuveer Singh Mali,Peilin Ma,Anindya Chatterjee,Baskar Ramdas,Emily K. Sims,Veerendra Munugalavadla,Joydeep Ghosh,Ray R. Mattingly,Valeria Visconte,Ramon V. Tiu,Cornelis P. Vlaar,Suranganie Dharmawardhane,Reuben Kapur +13 more
TL;DR: Pak and Rac GTPases, including Vav1, are identified as potential therapeutic targets in MPN and AML involving an oncogenic form of KIT.
Journal ArticleDOI
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
Veerendra Munugalavadla,Sanjeev Mariathasan,Dionysos Slaga,Changchun Du,Leanne Berry,G Del Rosario,Yibing Yan,M Boe,Liping L. Sun,Lori Friedman,Marta Chesi,P. Leif Bergsagel,Allen J. Ebens +12 more
TL;DR: In vivo GDC-0941 has anti-myeloma activity and significantly increases the activity of the standard of care agents in several murine xenograft tumor models (additional tumor growth inhibition of 37–53% (Dex) and 22–72% (lenalidomide)).
Journal ArticleDOI
The p85α subunit of class IA phosphatidylinositol 3-kinase regulates the expression of multiple genes involved in osteoclast maturation and migration
Veerendra Munugalavadla,Veerendra Munugalavadla,Sasidhar Vemula,Emily Sims,Subha Krishnan,Shi Chen,Jincheng Yan,Huijie Li,Paul J. Niziolek,Paul J. Niziolek,Clifford M. Takemoto,Alexander G. Robling,Feng Chun Yang,Reuben Kapur +13 more
TL;DR: It is demonstrated that osteoclasts express multiple regulatory subunits of class IA phosphatidylinositol 3-kinase (PI3-K) although the expression of the full-length form of p85α is most abundant.